September 17, 2014

Bruker announces first Customer Installation of its Preclinical Magnetic Particle Imaging (MPI) Scanner at the University Medical Center Hamburg, Germany.

PR17092014 MPI UKE Hamburg

3D MPI image overlay on MRI reference image. Courtesy University Medical Center Hamburg-Eppendorf (UKE), Germany.

SEOUL, Korea – September 17, 2014 –  Bruker announces the first customer installation of its MPI PreClinical, a preclinical Magnetic Particle Imaging (MPI) scanner, at the University Medical Center Hamburg-Eppendorf (UKE), Germany.  Significantly, this marks the first time that MPI technology has been delivered in a commercial system.  Preclinical MPI is an entirely new technology for in vivo imaging of small animals used in translational research.

The new MPI PreClinical scanner was introduced in 2013 and is the result of Bruker’s collaboration with Royal Philips (NYSE: PHG, AEX: PHIA).  It combines Bruker’s leadership in preclinical imaging with Philips’ strengths in medical imaging. MPI was invented by scientists at Philips and uses the detection of magnetic iron-oxide nanoparticles injected into the bloodstream to produce three-dimensional images at millisecond intervals, providing the potential for real-time 3D imaging in vivo.  MPI’s high time-resolution allows researchers to investigate an extensive range of dynamic issues, e.g. in cardiovascular research, which cannot be studied using other techniques.

Dr. Wulf I. Jung, President of Bruker’s Preclinical Imaging division, stated, “This first successful installation of a commercial preclinical imaging system, and our ongoing collaboration with Philips on this exciting new technology, is very significant.  Magnetic Particle Imaging is a novel imaging modality that is expected to enable scientists to address an extensive range of new issues in preclinical research.  MPI complements Bruker’s fast-growing preclinical imaging product portfolio that includes: MRI, PET, SPECT, micro-CT, optical molecular imaging and X-ray. It offers great potential for small animal imaging, especially when combined with high spatial resolution morphological MRI.”

About Bruker Corporation
Bruker (NASDAQ: BRKR) is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for in vitro diagnostics, industrial and applied analysis.  
For more information on MPI PreClinical, please visit www.bruker.com/mpi

Media Contact:    

Dr. Thorsten Thiel
Director of Marketing Communications
T: +49 (721) 5161–6500    
E: thorsten.thiel@bruker.com